Different effects of oral and transdermal hormonal replacement on prostacyclin and thromboxane A2
- 21 June 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health
- Vol. 89 (1) , 104-107
- https://doi.org/10.1016/s0029-7844(96)00379-1
Abstract
Objective: To elucidate the mechanism of cardiovascular protection of hormone replacement therapy (HRT) by comparing the effect of oral and transdermal HRTs on the production of antiaggregatory, vasodilatory prostacyclin, and its endogenous antagonist, thromboxane A2. Methods: Oral estradiol (2.0 mg/d) plus norethisterone acetate (1.0 mg/d) (n = 13) or transdermal estradiol (50 μg/d) plus medroxyprogesterone acetate (10 mg/d) as 12-day courses at 4-week intervals (n = 13) were given to postmenopausal women. Urinary excretion of the metabolites of prostacyclin, ie, 6-ketoprostaglandinF1α and 2,3-dinor-6- ketoprostaglandinF1α, as well as those of thromboxane A2, ie, thromboxane B2 and 2,3-dinor-thromboxane B2, were measured by radioimmunoassays, after purification by extraction and high performance liquid chromatography, before and during the sixth and the 12th treatment cycles. Results: Oral HRT stimulated excretion of thromboxane B2 from 3.4 ± 0.7 ng/mmol creatinine to 4.5 ± 1.5 (mean ± standard deviation, P <.05) and that of 2,3-dinorthromboxane B2 from 16.6 ± 8.0 ng/mmol creatinine to 26.2 ± 10.7 (P <.01), and thus led to the dominance of thromboxane A2. No changes in prostanoids occurred during transdermal HRT. Conclusions: The effects of various HRTs on prostanoids may significantly differ.Keywords
This publication has 0 references indexed in Scilit: